Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT00961909
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1036
- Registration Number
- NCT00960661
- Locations
- 🇬🇧
Research Site, Wakefield, United Kingdom
Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers
- Conditions
- HealthyDiabetes
- Interventions
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT00959101
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 38
- Registration Number
- NCT00951899
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
PED/PEA-15 Protein, PCOS, Obesity, Insulin Sensitivity Indexes, Metformin, Oral Contraceptives
- Conditions
- Polycystic Ovarian SyndromeInsulin Sensitivity
- Interventions
- Drug: oral contraceptiveDrug: Metformin
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 20
- Registration Number
- NCT00948402
Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects
- Conditions
- Healthy
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2009-07-23
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT00944346
- Locations
- 🇺🇸
Gateway Medical Research, Inc., St, Charles, Missouri, United States
Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects
- Conditions
- Healthy
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2009-07-23
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT00944177
- Locations
- 🇺🇸
Gateway Medical Research, Inc., St, Charles, Missouri, United States
Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 60
- Registration Number
- NCT00941382
- Locations
- 🇲🇽
Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico
Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin
- Conditions
- Type 2 Diabetic PatientsInsufficient Metabolic ControlOAD Treatment
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT00941148
- Locations
- 🇩🇪
ikfe GmbH, Clinic Department, Mainz, RLP, Germany
Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 24
- Registration Number
- NCT00941239
- Locations
- 🇲🇽
Pharmacology and toxicology department, UANL, Monterrey, Nuevo León, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.